Adrenocortical Carcinoma - Epidemiology Forecast - 2034

Adrenocortical Carcinoma - Epidemiology Forecast - 2034

Key Highlights

DelveInsight’s analyst projects that the total incident cases of Adrenocortical Carcinoma (ACC) in the 7MM were ~1,245 in 2023 and these cases are going to increase during the forecast period (2024–2034). This increase in growth can be attributed to growing awareness, ultimately leading to an increase in the occurence of ACC.

According to DelveInsight's analysis, approximately 27% of the total incident cases of ACC in the 7MM were in the United States. Our estimations indicate that in 2023, the EU4 and the UK collectively represented nearly 658 incident cases of ACC.

DelveInsight's analysis indicates that, in 2023, the stage-specific incident cases of ACC in the United States were highest in stage III, with 130 cases, and lowest in stage I, with 50 cases. These numbers are expected to rise significantly, growing at a notable compound annual growth rate (CAGR) over the forecast period.

According to DelveInsight's analysis, in 2023, Japan's gender-specific incident cases of ACC were predominantly female, accounting for 70% of cases, while males represented 30%. This distribution underscores a significant gender disparity in ACC incidence, pointing to potential biological or environmental factors influencing higher incidence in females.

DelveInsight’s “Adrenocortical Carcinoma (ACC) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Adrenocortical Carcinoma (ACC), historical and forecasted epidemiology of Adrenocortical Carcinoma (ACC) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Adrenocortical Carcinoma (ACC) Understanding

Adrenocortical Carcinoma (ACC) Overview

ACC is a rare and aggressive cancer originating in the adrenal cortex above the kidneys. Risk factors include genetic syndromes like Li–Fraumeni and Beckwith–Wiedemann, inherited mutations, family history of adrenal tumors, and radiation exposure.

ACC progresses through stages based on tumor size and metastasis. Early stages involve confined tumors, while later stages may see invasion into nearby tissues or distant spread to organs like the liver, lungs, or bones.

Adrenocortical Carcinoma (ACC) Diagnosis

ACC diagnosis entails a comprehensive approach, starting with medical history review and physical examination to detect adrenal gland abnormalities. Imaging tests like CT, MRI, and PET scans visualize tumors and their extent, while blood and urine tests measure hormone levels and metabolic markers. Biopsies, though definitive, carry risk and aren't always performed. Genetic testing may be advised, particularly with familial history. Staging scans inform treatment decisions, often involving surgery, chemotherapy, radiation, or targeted therapy, supported by multidisciplinary healthcare teams.

Diagnosing ACC presents considerable challenges due to its rarity and overlap in symptoms with other adrenal disorders, often leading to delayed identification. Imaging and hormonal testing are typically required, but distinguishing ACC from benign adrenal tumors remains complex. Furthermore, early-stage ACC can be asymptomatic, complicating detection until advanced stages. Limited awareness and non-specific symptoms contribute to misdiagnosis, underscoring the need for improved diagnostic tools and screening protocols.

Further details related to diagnosis are provided in the report…

Adrenocortical Carcinoma (ACC) Epidemiology

For the purpose of designing the patient-based model for ACC, the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of ACC, Stage-specific Incident Cases of ACC, Gender-specific Incident Cases of ACC, and Age-specific Incident Cases of ACC in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

As per DelveInsight’s estimates, Japan accounted for nearly 20% of the Total Incident Cases of ACC in the 7MM in 2023.

According to the analysis, among the EU4 and the UK, Germany reported the highest incidence of ACC with approximately 168 cases, followed by France with nearly 136 cases. Spain had the lowest incidence, with 94 cases. These figures are projected to increase by 2034.

The Gender-specific Cases of ACC in the US were ~195 for females and ~145 for males in 2023 and are expected to increase within the forecast period (2024–2034). The increased incidence in females is likely due to a combination of factors, including genetics, environmental factors, and healthcare inequalities, among others.

According to DelveInsight's expert analysis, the age-specific cases of Adrenocortical Carcinoma (ACC) were categorized into <20 years, 20–40 years, 40–60 years, and >60 years. In 2023, the highest number of cases (~132) was observed in the >60 years age group in the US.

DelveInsight’s analysis for 2023 indicates that stage-specific incident cases of ACC in Japan were divided into Stage I, Stage II, Stage III, and Stage IV. The highest incidence was observed in Stage IV with approximately 102 cases, while Stages I and II had the lowest, at around 29 cases each. This variation reflects distinct disease progression rates. Projections suggest these numbers will increase significantly, showing a robust compound annual growth rate over the forecast period.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease incidence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Michigan, Ann Arbor, MI, US, Interfaith Medical Center, Brooklyn, NY, US, Würzburg University Hospital, Würzburg, Germany, Center Léon-Bérard, Department of Medical Oncology, Lyon, France, University-Hospital of Padua, Padua, Italy, Catalan Institute of Oncology, Barcelona, Spain, University Hospital of Wales, Cardiff, United Kingdom, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, and others were contacted. Their opinion helps understand and validate current disease incidence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of executive summary, descriptive overview of Adrenocortical Carcinoma (ACC), explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Adrenocortical Carcinoma (ACC) Report Insights

Patient Population

Country-wise Epidemiology Distribution

Total Incident Cases of ACC

Stage-specific Incident Cases of ACC

Gender-specific Incident Cases of ACC

Age-specific Incident Cases of ACC

Adrenocortical Carcinoma (ACC) Report Key Strengths

11 years Forecast

The 7MM Coverage

Adrenocortical Carcinoma (ACC) Epidemiology Segmentation

Adrenocortical Carcinoma (ACC) Report Assessment

Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Adrenocortical Carcinoma (ACC)? What will be the growth opportunities across the 7MM concerning the patient population of Adrenocortical Carcinoma (ACC)?

What is the historical and forecasted Adrenocortical Carcinoma (ACC) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Why is the incident cases of ACC in Japan lower than the US?

Which country has a high patient share for ACC?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Adrenocortical Carcinoma (ACC) incident cases in varying geographies over the coming years.

A detailed overview of Gender and Age-specific incidence of ACC, along with Age-specific incidence of ACC.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Adrenocortical Carcinoma (ACC) Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Adrenocortical Carcinoma (ACC) cases in 2023?

The highest cases of Adrenocortical Carcinoma (ACC) was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Adrenocortical Carcinoma (ACC) cases in 2023?

The highest cases of Adrenocortical Carcinoma (ACC) were found in the US among the 7MM in 2023.